Get the Stockscreener App
349.58
1.15%
3.98
After Hours:
347.65
-1.93
-0.55%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $349.58, with a volume of 3.45M.
It is up +1.15% in the last 24 hours and up +6.07% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$345.60
Open:
$348.76
24h Volume:
3.45M
Relative Volume:
1.35
Market Cap:
$188.67B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
24.31
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+3.80%
1M Performance:
+6.07%
6M Performance:
+5.97%
1Y Performance:
+21.76%
1-Day Range:
$347.66
$356.50
1-Week Range:
$322.30
$356.50
52-Week Range:
$267.83
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
349.58 | 186.52B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,131.42 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.77 | 549.25B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.23 | 397.42B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.79 | 297.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.95 | 281.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Goldman Sachs Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $389 - Moomoo
Is There Still Opportunity In Amgen (AMGN) After Its 24% One-Year Share Price Gain - simplywall.st
Is Oncology Approval And Autoimmune Data Momentum Altering The Investment Case For Amgen (AMGN)? - Yahoo Finance
Amgen: Time For An Upgrade? Yes, I Think So (NASDAQ:AMGN) - Seeking Alpha
Harvest Fund Management Co. Ltd Has $15.85 Million Holdings in Amgen Inc. $AMGN - MarketBeat
TD Asset Management Inc Has $120.20 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by Daiwa Securities Group Inc. - MarketBeat
Cibc World Market Inc. Acquires 7,112 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference - MarketBeat
Amgen Won't Face 'Nonsensical' Rodent Antibody IP At Trial - Law360
Real-World Evidence: Shaping Obesity Treatment Beyond Clinical Trials - Amgen
kidSTREAM Opening Brings Hands-On Science Learning to Families Near Amgen’s Headquarters - Amgen
Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Amgen Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
A Look at Amgen Inc (AMGN) After 3.0% Gain -- GF Value $353.21 v - GuruFocus
Archvest Wealth Advisors Inc. Buys Shares of 3,801 Amgen Inc. $AMGN - MarketBeat
28,909 Shares in Amgen Inc. $AMGN Acquired by Avalon Capital Management - MarketBeat
Assessing Amgen (AMGN) Valuation After Imdelltra Approval And Concerns Over Tavneos And Prolia - simplywall.st
Bob Bradway on AI: Reimagining the Future of Biotechnology - Amgen
Amgen Inc Stock (AMGN) Closed Up by 3.04% on Jun 3: Key Drivers Unveiled - TradingKey
Amgen Inc. stock (US0311621009): EU lung cancer approval draws focus as shares hold near USD 330 - AD HOC NEWS
Rare autoimmune drugs UPLIZNA and TAVNEOS show control with fewer steroids - Stock Titan
Oncolytic Virus Cancer Therapy Market Led by U.S. as Amgen and CG Oncology Advance Innovation - openPR.com
Amgen Shareholder Notice - TMX Newsfile
Natixis Advisors LLC Has $113.26 Million Holdings in Amgen Inc. $AMGN - MarketBeat
CIBC Asset Management Inc Buys 44,110 Shares of Amgen Inc. $AMGN - MarketBeat
Bridges Investment Management Inc. Lowers Holdings in Amgen Inc. $AMGN - MarketBeat
Bank of New York Mellon Corp Trims Position in Amgen Inc. $AMGN - MarketBeat
EU Approval Of IMDYLLTRA Puts Amgen’s Lung Cancer Ambitions In Focus - simplywall.st
Amgen (AMGN) Secures EU Approval for Imdelltra in Small Cell Lun - GuruFocus
Amgen Inc. stock (US0311621009): EU approves Imdylltra as shares ease from recent highs - AD HOC NEWS
The Next Era in Obesity Care - Amgen
Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication - Yahoo Finance
ANCA Vasculitis Market to Witness Transformational Growth - openPR.com
EC approval for Amgen’s Imdylltra - The Pharma Letter
BNP Paribas Acquires 38,554 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. stock (US0311621009): EU approval for IMDYLLTRA adds fresh catalyst - AD HOC NEWS
Amgen's Extensive-stage Small Cell Lung Cancer Immunotherapy Granted EU Marketing Authorization - Moomoo
Amgen Inc. stock underperforms Monday when compared to competitors - MarketWatch
EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER - PR Newswire
Amgen Inc. stock (US0311621009): Shares open lower in New York - AD HOC NEWS
Amgen shares dip amid rising selling pressure - Traders Union
When Culture Meets Care: Bringing Cardiovascular Screening to the Heart of New Orleans - Amgen
Here's Why Amgen (AMGN) is a Strong Momentum Stock - Yahoo Finance
(AMGN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Peapack Gladstone Financial Corp Sells 8,887 Shares of Amgen Inc. $AMGN - MarketBeat
MUFG Securities EMEA plc Boosts Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (AMGN) Stock Analysis: Navigating a 4.59% Potential Upside Amid Strong Revenue Growth - DirectorsTalk Interviews
Easterly Investment Partners LLC Reduces Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc stock (US0311621009): Nasdaq shares hold near 337 USD as investors weigh Q1 2026 results a - AD HOC NEWS
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.81%
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):